to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Efficacy of Bismuth/Amoxicillin/Potassium-competitive Acid Blocker Triple Therapy for the Treatment of Helicobacter Pylori Infection in Taiwan

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

Inclusion Criteria:

Subjects infected with Helicobacter pylori.

Exclusion Criteria:

1. Those who are allergic to the drugs used in this research.
2. Those who have had stomach surgery.
3. Those with severe liver cirrhosis or uremia or malignant tumors.
4. Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.